AGP Executive Report
Last update: 8 hours agoMedical Cannabis Evidence Check: A new JAMA review says medical cannabis may help some people with chronic noncancer pain, insomnia and anxiety, but the strongest support is limited by small studies and weak study design—while also flagging risks like cannabis use disorder and psychotic symptoms from high-potency products. CBD for Anxiety (India): Leiutis Pharma says India’s CDSCO approved Zenara Pharma’s synthetic cannabidiol oral solution (150 mg/mL) for mild-to-moderate anxiety disorders alongside CBT, with prescribing limited to psychiatrists and Phase III backing. Dementia Agitation Trial: A randomized, double-blind study presented at the Alzheimer’s Association conference found a THC/CBD combo (2 mg/100 mg twice daily) reduced agitation in late-stage dementia versus placebo, with benefits lasting through 12 weeks. Road Safety & Cannabis Impairment: Vermont is expanding training to spot cannabis-impaired drivers after crash data showed more cannabis-only incidents and fatalities; meanwhile Malaysia’s JPJ reported drug-positive commercial drivers often claimed they used substances to stay energized, including THC positives. Policy/Travel Warnings: Thailand tightened rules on cannabis in luggage, warning Americans could face up to 10 years in prison for cross-border transport without proper permissions. Regulated Market Moves (USVI): The Virgin Islands opened cannabis license applications with a Sept. 15 deadline, including cultivation, manufacturing, dispensary, and territory-wide micro-cultivation/research options.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
